key: cord-0901689-jlvmxhwu
authors: Belchamber, K. B.; Thein, O. S.; Hazeldine, J.; Grudzinska, F. S.; Hughes, M. J.; Jasper, A. E.; Yip, K. P.; Sapey, E.; Parekh, D.; Thickett, D. R.; Scott, A.
title: Altered neutrophil phenotype and function in non-ICU COVID-19 patients correlated with disease severity
date: 2021-06-08
journal: nan
DOI: 10.1101/2021.06.08.21258535
sha: 681dc467242ea8d40dbccbaf42fe0cc242c20219
doc_id: 901689
cord_uid: jlvmxhwu

Rational: Infection with the SARS-CoV2 virus is associated with elevated neutrophil counts. Evidence of neutrophil dysfunction in COVID-19 is based predominantly on transcriptomics or single functional assays. Cell functions are interwoven pathways, and so understanding the effect of COVID-19 across the spectrum of neutrophil function may identify tractable therapeutic targets. Objectives: Examine neutrophil phenotype and functional capacity in COVID-19 patients versus age-matched controls (AMC) Methods: Isolated neutrophils from 41 hospitalised, non-ICU COVID-19 patients and 23 AMC underwent ex vivo analyses for migration, bacterial phagocytosis, ROS generation, NET formation (NETosis) and cell surface receptor expression. DNAse 1 activity was measured, alongside circulating levels of cfDNA, MPO, VEGF, IL-6 and sTNFRI. All measurements were correlated to clinical outcome. Serial sampling on day 3-5 post hospitalisation were also measured. Results: Compared to AMC, COVID-19 neutrophils demonstrated elevated transmigration (p=0.0397) and NETosis (p=0.0366), but impaired phagocytosis (p=0.0236) associated with impaired ROS generation (p<0.0001). Surface expression of CD54 (p<0.0001) and CD11c (p=0.0008) was significantly increased and CD11b significantly decreased (p=0.0229) on COVID-19 patient neutrophils. COVID-19 patients showed increased systemic markers of NETosis including increased cfDNA (p=0.0153) and impaired DNAse activity (p<0.0.001). MPO (p<0.0001), VEGF (p<0.0001), TNFRI (p<0.0001) and IL-6 (p=0.009) were elevated in COVID-19, which positively correlated with disease severity by 4C score. Conclusion: COVID-19 is associated with neutrophil dysfunction across all main effector functions, with altered phenotype, elevated migration, impaired antimicrobial responses and elevated NETosis. These changes represent a clear mechanism for tissue damage and highlight that targeting neutrophil function may help modulate COVID-19 severity.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome 73 coronavirus 2 (SARS-CoV2) virus, was declared a global pandemic by The World Health 74

Organisation on 11 th March 2020 [1] . Up to 80% of people infected with SARS-CoV2 75 experience mild to moderate respiratory disease, but in 10-20% of cases, infection can 76 manifest as pneumonitis, with 5% progressing to acute respiratory distress syndrome (ARDS). 77

The overall worldwide mortality rate is 2.2% but this increases to up to 50% in the presence 78

of ARDS [2] . 79 80

Dysregulated virus induced host-immune responses are thought to be the primary cause of 81

severe . Neutrophils are frontline effector cells that protect against rapidly 82 dividing pathogens and play a pivotal role in the antiviral immune response [4] . Early during 83

an inflammatory event, neutrophils migrate into lung tissue where they perform phagocytosis 84

and release proteases, reactive oxygen species (ROS) and as a later response, neutrophil 85 extracellular traps (NETs) to aid clearance of infection [5] .

Advanced age is a recognised risk factor for severe COVID-19, including the development of 88 ARDS [6] [7] [8] . Ageing is associated with changes in neutrophil function, including reduced 89 migratory accuracy [9] , phagocytosis [10] and NETosis [11] , which may delay pathogen 90 clearance and increase bystander tissue injury. Further impairments in neutrophil function 91

have been observed in patients with pneumonia [12] , sepsis [13] and ARDS [14] . This 92 dysfunction is most apparent in older adults with severe infections [15] and is associated with 93

poor clinical outcomes [12, 13] . Importantly, these functional deficits appear amenable to 94 therapeutic correction, especially in early or less severe infective episodes, suggesting that 95 neutrophils, or their products, may form a tractable target in inflammatory disease [16, 17] . 96

There is some evidence that neutrophil dysfunction could be associated with distinct cellular 97 phenotypes within the neutrophil population, with immature, senescent, activated and pro-98 inflammatory neutrophils identified in age and disease [13, 18, 19] .

Emerging studies suggest that neutrophils are implicated in the pathogenesis of severe 101 COVID-19 and every reporting study has described cell dysfunction (or inferred cell 102 dysfunction through transcriptomics) which could contribute to tissue damage and secondary 103

infection [20] [21] [22] [23] [24] [25] [26] [27] However, studies have often been small, fail to provide age-matched 104 controls, assess patients on the intensive care unit (ICU) after a considerable delay since 105 symptom onset, and often consider neutrophil functions in isolation.

These are important considerations. As neutrophil functions change with age, age matched 108 controls are important to identify pathological differences. Although approximately 12% of 109 hospitalised COVID-19 require ICU support, the majority of hospital admissions and deaths 110 occur on non-ICU wards [28] ; understanding how to improve outcomes for this patient group 111

is vital. Most studies in sepsis have demonstrated cell function is more therapeutically 112 tractable during early disease (before ICU care is needed), so the timeliness of intervention is 113

important. Cell functions are enabled by interwoven cell pathways with important differences 114 in internal signalling; knowing which functions are impaired informs which therapeutic 115 strategies might restore/maintain all facets of cellular function. 116 117 118 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 119

We hypothesised that neutrophils from COVID-19 patients would exhibit diverse altered 120 effector functions and changes to phenotype, with the degree of dysfunction associated with 121 adverse patient outcomes.

This study aimed to perform, for the first time, a comprehensive assessment of ex vivo 124 neutrophil phenotype and function in a statistically powered cohort of hospitalised, non-ICU 125 SARS-CoV2 infected patients compared to aged-matched controls and investigate 126 relationships with clinical outcomes. 127 128

Methods 129

Healthy donor and patient recruitment 130

Recruitment is summarised in Figure 1 Age matched controls (AMC) were either recruited from patients attending pre-booked face-152

to-face outpatient appointments or from hospital staff. AMC had no evidence of acute illness 153

including COVID-19 within the last two weeks, as assessed by a respiratory physician, and met 154 the other exclusion criteria described above.

Additional details on methodology are provided in the online supplement. These methods 157

include; plasma collection, neutrophil isolation by Pecoll gradient centrifugation, 158

phagocytosis of fluorescent S. pneumoniae, NETosis by release of cell-free (cf)DNA, transwell 159 migration, phenotyping by flow cytometry, serum DNase-1 activity assay, plasma cfDNA 160 quantification, citrullinated histone H3 detection and plasma biomarker quantification.

Statistics 163

Statistical analysis is described in the online supplement. A power calculation performed on 164 isolated neutrophil NETosis data (80%, alpha 0.05) suggested 18 participants were required 165 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 8, 2021. Figure 2A ). Migration was not 186 associated with 4C score (p=0.5575, Supplementary Figure 5A ), or survival at 28 days 187 (p=0.2563, Supplementary Figure 6A ). There was no change in migration at follow up 188 (p=0.1641, Supplementary Figure 4A ).

Neutrophil phagocytosis is impaired in Neutrophil phagocytosis of S. pneumoniae was significantly decreased in COVID-19 patients 192 compared to AMC (Median fluorescence intensity (MFI): 8.0 (4.2) AMC vs. 6.6 (2.6) 193 p<0.0236, Figure 2B ). Phagocytosis was not associated with 4C score (p=0.3257, 194

Supplementary Figure 5B ) or survival at 28 days (p=0.9228, Supplementary Figure 6B ). There 195 were no differences in neutrophil viability between patient groups or treatment conditions 196 (p=0.6726, Supplementary Figure 3A ).

Neutrophil derived ROS generation following phagocytosis is impaired in Cytoplasmic ( However, no differences were observed in cROS levels in either resting (p=0.999) or 204 stimulated (p=0.3946) neutrophils between study groups ( Figure 2C ).

Compared to resting neutrophils, n/mROS levels were significantly higher after phagocytosis 207 in neutrophils isolated from AMC (MFI: 21.8 (21) baseline vs. 32.0 (38), p<0.0001), but not in 208

COVID-19 patients (MFI: 18.9 (12) baseline vs. 21.2 (12), p=0.0610). No significant differences 209

were found in the levels of n/mROS in resting neutrophils (MFI: 21.8 (21) AMC vs. 18.9 (12) 210

COVID-19, p=0.0610). However, reduced levels of n/mROS were measured in neutrophils 211 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.08.21258535 doi: medRxiv preprint isolated from COVID-19 patients following phagocytosis when compared to AMC (MFI: 32.0 212 (38) AMC vs. 21.2 (12) COVID-19, p<0.0001, Figure 2D ).

Neutrophil NETosis is elevated in COVID-19 215

Higher levels of cfDNA were detected in supernatants obtained from COVID-19 patient 216 neutrophils post-PMA treatment compared to AMC (fold change in absorbance of neutrophils 217 stimulated with PMA vs. vehicle control: 1.29 (0.32) AMC vs. 1.53 (1.66) COVID-19, p=0.0366, 218 Figure 3A ). There were no differences in resting neutrophils NET production between COVID 219 patients and AMC (Supplementary Figure S3 ). When COVID-19 patients were stratified by 220 disease severity, more severe disease was associated with increased NETosis (fold change: 221

1.17 (0.35) Low 4C vs. 1.41 (0.80) High 4C, p=0.0118, Figure 3B .

At hospital admission, COVID-19 patients presented with higher concentrations of plasma 224 cfDNA compared to AMC (621ng/ml (1324) AMC vs. 1071ng/ml (856) COVID-19, p=0.0153, 225

Figure3C), which persisted at Day 3-5 day (p=0.0186, Figure. 3D).

To determine whether neutrophils, via NETosis, were a source of the cfDNA, plasma samples 228

were screened for the presence of CitH3, a protein that decorates the DNA backbone of NETs 229

[33]. Western blotting revealed the presence of CitH3 in 6 out of 8 samples analysed (75%, 230

Supplementary Figure 7) . 231 232

Using NETs as a substrate, serum DNase activity was lower in COVID-19 patients at the time 233

of hospital admission when compared to AMCs (% degradation: 88.4% (93) AMC vs. 12.8% 234 (49), p<0.0001, Figure 3E ).

Neutrophil phenotype is altered in COVID-19 237

To determine whether changes observed in neutrophil function were associated with 238 phenotype, surface expression of key surface molecules were investigated by flow cytometry.

A table of percentage receptor expression and MFI is shown in table 2.

Both the percentage of neutrophils expressing the activation marker CD11b (81% (8.9) AMC 242 vs. 67.8% (43.9) COVID-19, p=0.0229), and its surface expression (MFI:343 (119) AMC vs. 40 243

(141) COVID-19, p=0.0003, Figure 4A ) were reduced in COVID-19 patients. Expression of the 244 adhesion molecule CD11c was also elevated in COVID-19 patients (MFI: 220 (1274) AMC vs. 245

1148 (670) COVID-19, p<0.0008, Figure 4B ).

Both the percentage of neutrophils expressing CD54, a marker of reverse transmigration 248 (33.4% (35.3) AMC vs. 71.3% (21.2) COVID-19, p<0.0001, Figure 4C ) and its surface expression 249

(MFI: 21 (38) AMC vs. 73 (58) COVID-19, p=0.0008 Figure 4D ) were elevated in COVID-19 250

patients.

Expression of CD66b, CD62L, CD10, CXCR2, CXCR4 and PD-L1 did not differ between AMC and 253 COVID-19 patients (see table 2 ). There was no association of neutrophil phenotypic marker 254 expression with 4C severity score, or in survivors and non-survivors.

On day 3-5 follow-up, relative to baseline readings, there was a decrease in CXCR2 expression 257

(MFI: 1960 (1601) Day 1 vs. 1126 (1262) Day 3-5, p=0.0322, Figure 4E ) and a significant 258 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.08.21258535 doi: medRxiv preprint increase in CXCR4 expression (MFI: 1785 (3951) Day 1 vs. 10248 (16483) Day 3-5, p=0.0273, 259 Figure 4F ). COVID-19 patients showed elevated levels of IL-6 (p<0.009, Figure 5A ), VEGF (p<0.0001, 265

Figure5B), sTNFRI (p<0.0001, Figure 5C ), and MPO (p<0.0001, Figure 5D ), but not GM-CSF 266 (p=0.3375, Figure 5E ) when compared to AMC.

Only 2 activity. We also show an altered but distinct neutrophil phenotype, not compatible with a 288 purely activated, immature, senescent or anti-inflammatory phenotype as described before 289

(summarised in Figure 6 ). Our data suggests the energetics of the cells were not overtly 290 compromised, as some "high energy-consuming" functions (such as migration [35] CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. Limitations 384

This study was limited due to the safety measures required. All experiments were carried out 385 within a BSL2 hood and methods chosen based on tolerance to inactivation/fixation with 4% 386 PFA. Our patients did not include an ICU group, however, mild-moderate disease forms a 387 larger proportion of overall COVID-19 patients, and we believe it is this point in the patient 388 pathway which holds most potential for successful intervention.

Conclusion 391 Our study shows that moderate COVID-19 is associated with alterations in neutrophil 392 phenotype, increased migratory capacity and NETosis, and impaired antimicrobial function 393

which contributes to the severity of COVID-19. Elevated NETosis in the lung is associated with 394 disease severity, and elevated systemic NET production is likely to contribute to inflammation, 395 which may drive ARDS associated damage, and thrombosis. Targeting neutrophils and their 396 downstream effectors may be beneficial in the treatment of COVID-19. 397 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. Percentage of cells expressing, or MFI of isolated neutrophil cell surface markers measured 414 by flow cytometry in AMC (n=22) or COVID-19 patients (n=34). Data displayed as median 415 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 8, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.08.21258535 doi: medRxiv preprint Figure 3 ✱✱✱ . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.08.21258535 doi: medRxiv preprint Figure 5 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.08.21258535 doi: medRxiv preprint 831

Figure 6 832 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted June 8, 2021. ; https://doi.org/10.1101/2021.06.08.21258535 doi: medRxiv preprint

WHO Declares COVID-19 a Pandemic

Tissue-Specific Immunopathology in Fatal COVID-19

Neutrophils in viral infections: Current concepts and 435 caveats

Neutrophils in the lung: "the first responders". Cell and tissue research

Clinical features and short-term outcomes of 221 patients with 439 COVID-19 in Wuhan

Poor COVID-19 outcomes and deaths linked to advanced age and pre-441 existing conditions. Cancer

Aging in COVID-19: Vulnerability, immunity and intervention. Ageing 443 Res Rev

Phosphoinositide 3-kinase inhibition restores neutrophil accuracy in 445 the elderly: toward targeted treatments for immunosenescence

Senescence in innate immune responses: reduced neutrophil 448 phagocytic capacity and CD16 expression in elderly humans

Impaired neutrophil extracellular trap formation: a novel defect in 451 the innate immune system of aged individuals

Neutrophils in community-acquired pneumonia: parallels in 453 dysfunction at the extremes of age

Sepsis Induces a Dysregulated Neutrophil Phenotype That Is 455 Associated with Increased Mortality

Acute Respiratory Distress Syndrome Neutrophils Have a Distinct 457 Phenotype and Are Resistant to Phosphoinositide 3-Kinase Inhibition

Pulmonary infections in the elderly lead to impaired neutrophil 460 targetting, which is improved by simvastatin. American journal of respiratory and 461 critical care medicine

Statin therapy and autoimmune disease: 463 from protein prenylation to immunomodulation

Simvastatin Improves Neutrophil Function and Clinical Outcomes in 466

A Pilot Randomized Controlled Clinical Trial

Inflammation and neutrophil immunosenescence 469 in health and disease: Targeted treatments to improve clinical outcomes in the elderly

Neutrophil: A Cell with Many Roles in Inflammation or Several Cell 472 Types?

Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-474 19. Front Immunol

Disease severity-specific neutrophil signatures in blood 476 transcriptomes stratify COVID-19 patients

Severe COVID-19 Is Marked by a Dysregulated Myeloid 478 Cell Compartment

Neutrophil extracellular traps contribute to immunothrombosis 480 in COVID-19 acute respiratory distress syndrome

Complement and tissue factor-enriched neutrophil extracellular 483 traps are key drivers in COVID-19 immunothrombosis

Neutrophil extracellular traps in COVID-19

The emerging role of neutrophil extracellular traps in severe acute 487 respiratory syndrome coronavirus 2 (COVID-19). Sci Rep

Vascular occlusion by neutrophil extracellular traps in COVID-19

Ethnicity and risk of death in patients hospitalised for COVID-19 491 infection in the UK: an observational cohort study in an urban catchment area

Repurposing treatments to enhance innate immunity. Can statins 494 improve neutrophil functions and clinical outcomes in COPD? Journal of clinical 495 medicine

Risk stratification of patients admitted to hospital with covid-19 497 using the ISARIC WHO Clinical Characterisation Protocol: development and 498 validation of the 4C Mortality Score. Bmj, 2020. 370: p. m3339. 499 31. COVID-19 rapid guideline: Managing COVID-19

Acute respiratory distress syndrome: the Berlin Definition

Specific post-translational histone modifications of neutrophil 504 extracellular traps as immunogens and potential targets of lupus autoantibodies

Chemokines acting via CXCR2 and CXCR4 control the release of 560 neutrophils from the bone marrow and their return following senescence

A single-cell atlas of the peripheral immune response in patients with 563 severe COVID-19

Identification of a phenotypically and functionally distinct 565 population of long-lived neutrophils in a model of reverse endothelial migration

Kinetics of peripheral blood neutrophils in severe 568 coronavirus disease 2019

Association of COVID-19 inflammation with activation of the C5a-570 C5aR1 axis

Neutrophil and monocyte dysfunctional effector response 572 towards bacterial challenge in critically-ill COVID-19 patients. bioRxiv, 2020. 573 62

Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in 576 Bronchiectasis

Neutrophil extracellular traps and thrombosis in COVID-19